NCT07104331View on ClinicalTrials.gov

SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

August 30, 2029

Study Completion Date

August 30, 2029

Conditions
Epithelioid Hemangioendothelioma (EHE)
Interventions
DRUG

nab-Sirolimus

nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle.

Trial Locations (6)

10065

Sloan Kettering Institute for Cancer Research, New York

63130

Washington University St. Louis, St Louis

80203

University of Colorado, Aurora

94305

Stanford University, Stanford

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Sarcoma Alliance for Research through Collaboration

OTHER